Marcello Leopoldo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1629523/publications.pdf

Version: 2024-02-01

139 papers	3,639 citations	109137 35 h-index	189595 50 g-index
140 all docs	140 docs citations	140 times ranked	3712 citing authors

#	Article	IF	Citations
1	The Need To Improve Reporting of the Pharmacological Action of New Molecules. ACS Chemical Neuroscience, 2022, , .	1.7	0
2	Behavioral, Anti-Inflammatory, and Neuroprotective Effects of a Novel FPR2 Agonist in Two Mouse Models of Autism. Pharmaceuticals, 2022, 15, 161.	1.7	8
3	In Vitro and In Silico Analysis of the Residence Time of Serotonin 5-HT₇ Receptor Ligands with Arylpiperazine Structure: A Structureâ€“Kinetics Relationship Study. ACS Chemical Neuroscience, 2022, 13, 497-509.	1.7	3
4	Design and Synthesis of Arylpiperazine Serotonergic/Dopaminergic Ligands with Neuroprotective Properties. Molecules, 2022, 27, 1297.	1.7	1
5	Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders. Journal of Medicinal Chemistry, 2022, 65, 5004-5028.	2.9	7
6	Design, Synthesis, and Characterization of a Novel Fluoroprobe for Live Human Islet Cell Imaging of Serotonin 5â€HT _{1A} Receptor. ChemMedChem, 2022, , .	1.6	1
7	Activation of 5-HT1A and 5-HT7 receptors enhanced a positively reinforced long-term memory. Behavioural Brain Research, 2021, 397, 112932.	1.2	6
8	Stimulation of the Serotonin Receptor 7 Restores Brain Histone H3 Acetylation and MeCP2 Corepressor Protein Levels in a Female Mouse Model of Rett Syndrome. Journal of Neuropathology and Experimental Neurology, 2021, 80, 265-273.	0.9	1
9	Knowledge-Based Design of Long-Chain Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as Potential Candidates for Treatment of Autism Spectrum Disorder. ACS Chemical Neuroscience, 2021, 12, 1313-1327.	1.7	10
10	Serotonin 5â€HT7 receptors require cyclinâ€dependent kinase 5 to rescue hippocampal synaptic plasticity in a mouse model of Fragile X Syndrome. European Journal of Neuroscience, 2021, 54, 4124-4132.	1.2	6
11	Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology. Pharmacological Reports, 2021, 73, 1004-1019.	1.5	29
12	Multi-Target Directed Ligands (MTDLs) Binding the Ïƒ1 Receptor as Promising Therapeutics: State of the Art and Perspectives. International Journal of Molecular Sciences, 2021, 22, 6359.	1.8	13
13	The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Exhibits Anti-Inflammatory Activity in LPS-Stimulated Organotypic Hippocampal Cultures. Cells, 2021, 10, 1524.	1.8	13
14	The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Improves Ex Vivo and In Vivo Amyloid Beta (1â€“42)-Induced Neuroinflammation in Mouse Models of Alzheimerâ€™s Disease. Molecular Neurobiology, 2021, 58, 6203-6221.	1.9	10
15	Time-Dependent Protective and Pro-Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-ÎºB and MAPKs Pathways. Cells, 2021, 10, 2373.	1.8	14
16	Low Basicity as a Characteristic for Atypical Ligands of Serotonin Receptor 5-HT2. International Journal of Molecular Sciences, 2021, 22, 1035.	1.8	3
17	G-Protein Coupled Receptors Involved in the Resolution of Inflammation: Ligands and Therapeutic Perspectives. Mini-Reviews in Medicinal Chemistry, 2021, 20, 2090-2103.	1.1	10
18	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews, 2021, 73, 310-520.	7.1	127

#	Article	IF	Citations
19	Why PB28 Could Be a Covid 2019 Game Changer?. ACS Medicinal Chemistry Letters, 2020, 11, 2048-2050.	1.3	6
20	Mitochondrial Membranes of Human SH-SY5Y Neuroblastoma Cells Express Serotonin 5-HT7 Receptor. International Journal of Molecular Sciences, 2020, 21, 9629.	1.8	4
21	Privileged scaffold-based design to identify a novel drug-like 5-HT7 receptor-preferring agonist to target Fragile X syndrome. European Journal of Medicinal Chemistry, 2020, 199, 112395.	2.6	9
22	The Contribution of Formyl Peptide Receptor Dysfunction to the Course of Neuroinflammation: A Potential Role in the Brain Pathology. Current Neuropharmacology, 2020, 18, 229-249.	1.4	21
23	The microRNA-29a Modulates Serotonin 5-HT7 Receptor Expression and Its Effects on Hippocampal Neuronal Morphology. Molecular Neurobiology, 2019, 56, 8617-8627.	1.9	23
24	Prior Activation of 5-HT7 Receptors Modulates the Conditioned Place Preference With Methylphenidate. Frontiers in Behavioral Neuroscience, 2019, 13, 208.	1.0	3
25	An updated patent review on P-glycoprotein inhibitors (2011-2018). Expert Opinion on Therapeutic Patents, 2019, 29, 455-461.	2.4	49
26	Aurantiamide-related dipeptide derivatives are formyl peptide receptor 1 antagonists. MedChemComm, 2019, 10, 2078-2088.	3.5	3
27	High-affinity sigma-1 (Ïƒ₁) receptor ligands based on the Ïƒ₁ antagonist PB212. Future Medicinal Chemistry, 2019, 11, 2547-2562.	1.1	6
28	Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder. Neuropharmacology, 2019, 144, 104-114.	2.0	25
29	Structural insights into serotonin receptor ligands polypharmacology. European Journal of Medicinal Chemistry, 2018, 151, 797-814.	2.6	7
30	Activation of 5â€<scp>HT</scp>7 receptor by administration of its selective agonist, <scp>LP</scp>â€211, modifies explorativeâ€curiosity behavior in rats in two paradigms which differ in visuospatial parameters. CNS Neuroscience and Therapeutics, 2018, 24, 712-720.	1.9	9
31	Novel ⁶⁴Cu Labeled RGD₂-BBN Heterotrimers for PET Imaging of Prostate Cancer. Bioconjugate Chemistry, 2018, 29, 1595-1604.	1.8	22
32	Activation of Serotonin 5-HT7 Receptors Modulates Hippocampal Synaptic Plasticity by Stimulation of Adenylate Cyclases and Rescues Learning and Behavior in a Mouse Model of Fragile X Syndrome. Frontiers in Molecular Neuroscience, 2018, 11, 353.	1.4	32
33	Structureâ€"Activity Relationships and Therapeutic Potentials of 5-HT₇ Receptor Ligands: An Update. Journal of Medicinal Chemistry, 2018, 61, 8475-8503.	2.9	39
34	Potentiation of capsaicin-induced neurogenic inflammation by 5-HT7 receptors in the rat hind paw: Involvement of calcitonin gen-related peptide. Peptides, 2018, 105, 1-6.	1.2	3
35	Serotonin 5â€<scp>HT</scp>7 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons. Journal of Neurochemistry, 2017, 141, 647-661.	2.1	66
36	Stimulation of the brain serotonin receptor 7 rescues mitochondrial dysfunction in female mice from two models of Rett syndrome. Neuropharmacology, 2017, 121, 79-88.	2.0	43

#	Article	IF	Citations
37	Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide. Bioorganic and Medicinal Chemistry, 2017, 25, 277-292.	1.4	4
38	Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. Journal of Medicinal Chemistry, 2017, 60, 9114-9141.	2.9	46
39	Functional N â€Formyl Peptide Receptorâ€...2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammationâ€Associated Oxidative Stress. ChemMedChem, 2017, 12, 1839-1847.	1.6	11
40	Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. European Journal of Medicinal Chemistry, 2017, 141, 703-720.	2.6	36
41	The brain-penetrant 5-HT 7 receptor agonist LP-211 reduces the sensory and affective components of neuropathic pain. Neurobiology of Disease, 2017, 106, 214-221.	2.1	40
42	LPâ€211, a selective 5â€HT₇ receptor agonist, increases noveltyâ€preference and promotes riskâ€prone behavior in rats. Synapse, 2017, 71, e21995.	0.6	13
43	AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists. Frontiers in Endocrinology, 2017, 8, 176.	1.5	4
44	Structural Determinants in the Binding of BB2 Receptor Ligands: In Silico, X-Ray and NMR Studies in PD176252 Analogues. Current Topics in Medicinal Chemistry, 2017, 17, 1599-1610.	1.0	8
45	Selective 5-HT7 receptor agonists LP 44 and LP 211 elicit an analgesic effect on formalin-induced orofacial pain in mice. Journal of Applied Oral Science, 2016, 24, 218-222.	0.7	8
46	Radiosynthesis and inÂvivo Evaluation of Carbonâ€11 (2S)â€3â€(1Hâ€Indolâ€3â€yl)â€2â€[[(4â€methoxyphenyl)carbamoyl]amino}â€Nâ€[1â€(5â€methoxypyridinâ€2 An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neuroinflammation. Chemistry and Biodiversity, 2016, 13, 875-883.	1.0	4
47	Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve inÂvitro microsomal stability: A case study. European Journal of Medicinal Chemistry, 2016, 120, 363-379.	2.6	14
48	Functionalized Coumarine Fragment to Obtain Fluorescent and Selective Pâ€Glycoprotein Ligands. Archiv Der Pharmazie, 2016, 349, 161-167.	2.1	3
49	The 5-HT7 receptor triggers cerebellar long-term synaptic depression via PKC-MAPK. Neuropharmacology, 2016, 101, 426-438.	2.0	46
50	Design and Synthesis of New Selective P-gp Substrates and Inhibitors. Current Pharmaceutical Design, 2016, 22, 5774-5778.	0.9	10
51	GR-127935-sensitive Mechanism Mediating Hypotension in Anesthetized Rats. Journal of Cardiovascular Pharmacology, 2015, 65, 335-341.	0.8	5
52	Stimulation of 5-HT7 receptor during adolescence determines its persistent upregulation in adult rat forebrain areas. Synapse, 2015, 69, 533-542.	0.6	9
53	Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics. Frontiers in Behavioral Neuroscience, 2015, 9, 62.	1.0	43
54	Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome. Frontiers in Behavioral Neuroscience, 2015, 9, 65.	1.0	48

#	Article	IF	Citations
55	Long-lasting beneficial effects of central serotonin receptor 7 stimulation in female mice modeling Rett syndrome. Frontiers in Behavioral Neuroscience, 2015, 9, 86.	1.0	44
56	Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of Î²-arrestin-2. Bioorganic and Medicinal Chemistry, 2015, 23, 4824-4830.	1.4	16
57	ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides, 2015, 64, 55-61.	1.2	21
58	Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2. Bioorganic and Medicinal Chemistry, 2015, 23, 3913-3924.	1.4	12
59	5-HT7 receptor activation: procognitive and antiamnesic effects. Psychopharmacology, 2015, 232, 595-603.	1.5	29
60	Persistent modification of forebrain networks and metabolism in rats following adolescent exposure to a 5-HT7 receptor agonist. Psychopharmacology, 2015, 232, 75-89.	1.5	33
61	Differential responses to acute administration of a new 5-HT7-R agonist as a function of adolescent pre-treatment: phMRI and immuno-histochemical study. Frontiers in Behavioral Neuroscience, 2014, 8, 427.	1.0	7
62	Pharmacological Stimulation of the Brain Serotonin Receptor 7 as a Novel Therapeutic Approach for Rett Syndrome. Neuropsychopharmacology, 2014, 39, 2506-2518.	2.8	64
63	ABC transporters in CSCs membranes as a novel target for treating tumor relapse. Frontiers in Pharmacology, 2014, 5, 163.	1.6	58
64	Design, Synthesis, Lipophilic Properties, and Binding Affinities of Potential Ligands in Positron Emission Tomography (PET) for Visualization of Brain Dopamine D₄ Receptors. Chemistry and Biodiversity, 2014, 11, 299-310.	1.0	5
65	In Vitro and In Vivo Evaluation of Nâ€{2â€[4â€(3â€Cyanopyridinâ€2â€yl)piperazinâ€1â€yl]ethyl}â€3â€[¹¹C]methoxybenzÂamide, a Positron Emission Tomography (PET) Radioligand for Dopamine D₄ Receptors, in Rodents. Chemistry and Biodiversity, 2014, 11, 1298-1308.	1.0	4
66	Emotional and risk seeking behavior after prepuberal subchronic or adult acute stimulation of 5-HT7-Rs in naples high excitability rats. Synapse, 2014, 68, 159-167.	0.6	18
67	Small and Innovative Molecules as New Strategy to Revert MDR. Frontiers in Oncology, 2014, 4, 2.	1.3	66
68	Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT7 receptor. Bioorganic and Medicinal Chemistry, 2014, 22, 1736-1750.	1.4	22
69	Interplay between Serotonin 5â€<scp>HT</scp>_{1A} and 5â€<scp>HT</scp>₇ Receptors in Depressive Disorders. CNS Neuroscience and Therapeutics, 2014, 20, 582-590.	1.9	102
70	PET Radiotracers for Imaging Pâ€glycoprotein: The Challenge for Early Diagnosis in AD. ChemMedChem, 2014, 9, 38-42.	1.6	6
71	Systemic administration and local microinjection into the central nervous system of the 5-HT7 receptor agonist LP-211 modify the sleep-wake cycle in the rat. Behavioural Brain Research, 2014, 259, 321-329.	1.2	19
72	Synthesis, radiolabeling and inÂvivo evaluation of [11C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT7 receptor. European Journal of Medicinal Chemistry, 2014, 79, 152-163.	2.6	26

#	Article	IF	Citations
73	Modulatory effects following subchronic stimulation of brain 5-HT7-R system in mice and rats. Reviews in the Neurosciences, 2014, 25, 383-400.	1.4	18
74	Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview. Reviews in the Neurosciences, 2014, 25, 401-15.	1.4	46
75	Prepuberal Stimulation of 5-HT7-R by LP-211 in a Rat Model of Hyper-Activity and Attention-Deficit: Permanent Effects on Attention, Brain Amino Acids and Synaptic Markers in the Fronto-Striatal Interface. PLoS ONE, 2014, 9, e83003.	1.1	20
76	Comparative evaluation of two dye probes in the rat everted gut sac model for unambiguous classification of P-gp substrate and inhibitor. Journal of Pharmacological and Toxicological Methods, 2013, 67, 5-8.	0.3	6
77	Novel highly potent serotonin 5-HT7 receptor ligands: Structural modifications to improve pharmacokinetic properties. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6083-6086.	1.0	6
78	The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways. Neuropharmacology, 2013, 67, 155-167.	2.0	62
79	Activityâ€“lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3728-3731.	1.0	11
80	3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: Molecular modeling of chiral recognition by FPR2. Biochemical Pharmacology, 2013, 85, 404-416.	2.0	26
81	Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters. Experimental Brain Research, 2013, 230, 569-582.	0.7	14
82	Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters. Bioorganic and Medicinal Chemistry, 2013, 21, 1324-1332.	1.4	26
83	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1370-1374.	1.0	6
84	The arylpiperazine derivatives N â€(4â€cyanophenylmethyl)â€4â€(2â€diphenyl)â€1â€piperazinehexanamide and N â€benzylâ€4â€(2â€diphenyl)â€1â€piperazinehexanamide exert a longâ€lasting inhibition of human serotonin 5â€HT7 receptor binding and cAMP signaling. Pharmacology Research and Perspectives, 2013, 1, e00013.	1.1	6
85	Biomarkers for the early diagnosis of Alzheimerâ€™s disease: The challenge of XXI century. Advances in Alzheimer's Disease, 2013, 02, 13-30.	0.3	10
86	Activatable Fluorescent Probes: A New Concept in Optical Molecular Imaging. Current Medicinal Chemistry, 2012, 19, 4731-4741.	1.2	35
87	Editorial [Hot Topic â€œFluorescent Probes: From Bench to Bedsideâ€•(Guest Editors: Enza Lacivita &) Tj ETQq1 1 0.784314 rgBT /Over	1.2	1
88	Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice. Neuropharmacology, 2012, 62, 833-842.	2.0	56
89	Activation of 5-HT7 Serotonin Receptors Reverses Metabotropic Glutamate Receptor-Mediated Synaptic Plasticity in Wild-Type and Fmr1 Knockout Mice, a Model of Fragile X Syndrome. Biological Psychiatry, 2012, 72, 924-933.	0.7	109
90	Investigations on the 1-(2-Biphenyl)piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin7(5-HT7) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo. Journal of Medicinal Chemistry, 2012, 55, 6375-6380.	2.9	35

#	Article	IF	Citations
91	The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opinion on Therapeutic Patents, 2012, 22, 887-902.	2.4	36
92	Microinjection of the 5-HT7 receptor antagonist SB-269970 into the rat brainstem and basal forebrain: Site-dependent effects on REM sleep. Pharmacology Biochemistry and Behavior, 2012, 102, 373-380.	1.3	12
93	A Benzopyrane Derivative as a Pâ€Glycoprotein Stimulator: A Potential Agent to Decrease Î²â€Amyloid Accumulation in Alzheimerâ€™s Disease. ChemMedChem, 2012, 7, 391-395.	1.6	14
94	EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Frontiers in Bioscience - Landmark, 2011, 16, 1811.	3.0	15
95	Increase of Capsaicin-Induced Trigeminal Fos-Like Immunoreactivity by 5-HT7 Receptors. Headache, 2011, 51, 1511-1519.	1.8	10
96	Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. , 2011, 129, 120-148.		168
97	Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors. Journal of Pharmacy and Pharmacology, 2010, 56, 247-255.	1.2	31
98	Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT1A receptor. Journal of Pharmacy and Pharmacology, 2010, 57, 1319-1327.	1.2	12
99	Synthesis and binding profile of constrained analogues of N-[4-(4-arylpiperazin-1-yl)butyl]-3-methoxybenzamides, a class of potent dopamine D3 receptor ligands. Journal of Pharmacy and Pharmacology, 2010, 58, 209-218.	1.2	11
100	Identification of a red-emitting fluorescent ligand for in vitro visualization of human serotonin 5-HT1A receptors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6628-6632.	1.0	15
101	Design, Synthesis, Radiolabeling, and in Vivo Evaluation of Carbon-11 LabeledN-[2-[4-(3-Cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a Potential Positron Emission Tomography Tracer for the Dopamine D4Receptors. Journal of Medicinal Chemistry, 2010, 53, 7344-7355.	2.9	12
102	LP-211 is a brain penetrant selective agonist for the serotonin 5-HT7 receptor. Neuroscience Letters, 2010, 481, 12-16.	1.0	73
103	5-HT7receptor modulators: a medicinal chemistry survey of recent patent literature (2004 â€“ 2009). Expert Opinion on Therapeutic Patents, 2010, 20, 739-754.	2.4	13
104	Developments in fluorescent probes for receptor research. Drug Discovery Today, 2009, 14, 706-712.	3.2	72
105	Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II. Bioorganic and Medicinal Chemistry, 2009, 17, 758-766.	1.4	11
106	Determination of 1-aryl-4-propylpiperazine pKa values: The substituent on aryl modulates basicity. Bioorganic and Medicinal Chemistry, 2009, 17, 1339-1344.	1.4	36
107	Synthesis and Characterization of Environment-Sensitive Fluorescent Ligands for Human 5-HT1AReceptors with 1-Arylpiperazine Structureâ€. Journal of Medicinal Chemistry, 2009, 52, 7892-7896.	2.9	22
108	Novel 4-(4-Aryl)cyclohexyl-1-(2-pyridyl)piperazines as Î”₈â^Î”₇ Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity. Journal of Medicinal Chemistry, 2008, 51, 7523-7531.	2.9	42

#	Article	IF	Citations
109	N-[Ï‰-[4-(2-Methoxyphenyl)-1-piperazinyl]alkyl]-2-quinolinamines as High-Affinity Fluorescent 5-HT1A Receptor Ligands. Journal of Medicinal Chemistry, 2008, 51, 1492-1495.	2.9	10
110	The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behavioural Brain Research, 2008, 191, 184-189.	1.2	49
111	Structural Modifications of N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-piperazinehexanamides: Influence on Lipophilicity and 5-HT₇ Receptor Activity. Part III. Journal of Medicinal Chemistry, 2008, 51, 5813-5822.	2.9	67
112	5-HT1A Receptor, an Old Target for New Therapeutic Agents. Current Topics in Medicinal Chemistry, 2008, 8, 1024-1034.	1.0	83
113	High-Affinity Dopamine D₃ Receptor Ligands as Potential Probes for Receptor Visualization. Journal of Medicinal Chemistry, 2007, 50, 5043-5047.	2.9	43
114	Structureâ^'Activity Relationship Study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a Class of 5-HT₇ Receptor Agents. 2. Journal of Medicinal Chemistry, 2007, 50, 4214-4221.	2.9	51
115	Bivalent ligand approach on 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine: Synthesis and binding affinities for 5-HT7 and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 5316-5321.	1.4	9
116	Design, Synthesis, and Binding Affinities of Potential Positron Emission Tomography (PET) Ligands for Visualization of Brain Dopamine D3Receptors. Journal of Medicinal Chemistry, 2006, 49, 358-365.	2.9	32
117	Selective Agents for Serotonin2C (5-HT2C) Receptor. Current Topics in Medicinal Chemistry, 2006, 6, 1927-1970.	1.0	13
118	Editorial [Hot Topic: Serotonin Receptors as Targets in Drug Discovery and Medicinal Chemistry (Guest Editor: Dr. Marcello Leopoldo)]. Current Topics in Medicinal Chemistry, 2006, 6, 1907-1907.	1.0	0
119	First Structureâ^'Activity Relationship Study on Dopamine D3 Receptor Agents with N-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamide Structure. Journal of Medicinal Chemistry, 2005, 48, 7919-7922.	2.9	30
120	11C-Labeling ofN-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide Derivatives and Evaluation as Potential Radioligands for PET Imaging of Dopamine D3Receptors. Journal of Medicinal Chemistry, 2005, 48, 7018-7023.	2.9	16
121	Structureâ^'Affinity Relationship Study onN-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-Piperazinealkylamides, a New Class of 5-Hydroxytryptamine7Receptor Agents. Journal of Medicinal Chemistry, 2004, 47, 6616-6624.	2.9	62
122	Serotonin7 Receptors (5-HT7Rs)and their Ligands. Current Medicinal Chemistry, 2004, 11, 629-661.	1.2	52
123	Synthesis and Structureâ^'Affinity Relationships of 1-[Ï‰-(4-Aryl-1-piperazinyl)alkyl]-1-aryl Ketones as 5-HT7 Receptor Ligands. Journal of Medicinal Chemistry, 2003, 46, 646-649.	2.9	53
124	Structureâ^'Affinity Relationship Study onN-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as Potent and Selective Dopamine D3Receptor Ligands. Journal of Medicinal Chemistry, 2002, 45, 5727-5735.	2.9	71
125	trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines:â€‰ A New Class of Potent and Selective 5-HT1A Receptor Ligands as Conformationally Constrained Analogues of 4-[3-(5-Methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1- arylpiperazines. Journal of Medicinal Chemistry, 2001, 44, 4431-4442.	2.9	26
126	A multireceptorial binding reinvestigation on an extended class of Ïƒ ligands: N-[Ï‰-(indan-1-yl and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Bioorganic and Medicinal Chemistry, 2001, 9, 1325-1335.	1.4	51

#	Article	IF	Citations
127	Determination of dopamine D4 receptor density in rat striatum using PB12 as a probe. European Journal of Pharmacology, 2001, 427, 1-5.	1.7	3
128	1-Substituted-4-[3-(1,2,3,4-tetrahydro-5- or 7-methoxynaphthalen-1-yl)propyl]piperazines: influence of the N -1 piperazine substituent on 5-HT 1A receptor affinity and selectivity versus D 2 and Î± 1 receptors. Part 6. Bioorganic and Medicinal Chemistry, 2000, 8, 873-881.	1.4	15
129	Carbon-11 pb-12: an attempt to visualize the dopamine d4 receptor in the primate brain with positron emission tomography. Nuclear Medicine and Biology, 2000, 27, 707-714.	0.3	24
130	A Structureâ^'Affinity Relationship Study on Derivatives ofN-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a High-Affinity and Selective D4Receptor Ligand. Journal of Medicinal Chemistry, 2000, 43, 270-277.	2.9	28
131	1-Aryl-4-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)alkyl]piperazines and Their Analogues:â€‰ Influence of the Stereochemistry of the Tetrahydronaphthalen-1-yl Nucleus on 5-HT1A Receptor Affinity and Selectivity versus Î±1 and D2 Receptors. 5. Journal of Medicinal Chemistry, 1999, 42, 490-496.	2.9	21
132	N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide:â€‰ A Potent and Selective Dopamine D4 Ligand. Journal of Medicinal Chemistry, 1998, 41, 4903-4909.	2.9	22
133	1-(2-METHOXYPHENYL)-4-ALKYLPIPERAZINES: EFFECT OF THE N-4 SUBSTITUENT ON THE AFFINITY AND SELECTIVITY FOR DOPAMINE D4 RECEPTOR. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1327-1330.	1.0	9
134	Structureâ^'Activity Relationship Studies on the 5-HT1AReceptor Affinity of 1-Phenyl-4-[Ï‰-(Î±- or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.9	23
135	1-Aryl-4-[(1-tetralinyl)alkyl]piperazines:â€‰ Alkylamido and Alkylamino Derivatives. Synthesis, 5-HT1A Receptor Affinity, and Selectivity. 3. Journal of Medicinal Chemistry, 1996, 39, 3195-3202.	2.9	31
136	High Affinity and Selectivity on 5-HT1A Receptor of 1-Aryl-4-[(1-tetralin)alkyl]piperazines. 2. Journal of Medicinal Chemistry, 1995, 38, 942-949.	2.9	92
137	Oxygen isosteric derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine. Journal of Medicinal Chemistry, 1992, 35, 3045-3049.	2.9	15
138	LCâ€“MS/MS Analysis on Infusion Bags and Filled Syringes of Decitabine: New Data on Physicochemical Stability of an Unstable Molecule. ACS Omega, 0, , .	1.6	1
139	5-HT7 Receptors Regulate Excitatory-Inhibitory Balance in Mouse Spinal Cord Dorsal Horn. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	3